|
Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer. |
| |
Kanwal Pratap Singh Raghav |
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen |
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen |
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst) |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Bayer; BMS; Eisai; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Taiho Pharmaceutical |
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst) |
| |
|
|
Stock and Other Ownership Interests - AbbVie |
| |
Martha Raluca Neagu Aristide |
|
Stock and Other Ownership Interests - AbbVie |
| |
Carla Biesdorf de Almeida |
|
Stock and Other Ownership Interests - AbbVie |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - AbbVie |
| |
|
Stock and Other Ownership Interests - Triumvira Immunologics, Inc |
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Natera (Inst); Pfizer; Roche/Genentech; Seagen; Taiho Oncology; Takeda |
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Roche/Genentech (Inst); Seagen (Inst) |
Expert Testimony - Seagen |
Travel, Accommodations, Expenses - Seagen |